E. Reid

发表

Non-Hodgkin's lymphomas, version 4.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Update on HHV-8-Associated Malignancies

M. Lechowicz, E. Reid, M. Sunil, 2010, Current infectious disease reports.

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

A. LaCasce, M. Dwyer, Deborah A. Freedman-Cass, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

An innovative system for 3 D clinical photography in the resource-limited settings

Yu-Tseung Liu, S. Esener, D. Carson, 2014 .

Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial

Sonali M. Smith, J. Friedberg, L. Swinnen, 2017, Leukemia & lymphoma.

Role of NF-κB Inhibitors in HIV-Related Malignancies

D. Dittmer, E. Reid, 2010 .

Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium

J. Sparano, W. Wachsman, P. Moore, 2016, Leukemia & lymphoma.

Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States.

M. Saag, S. Shrestha, J. Eron, 2013, AIDS research and human retroviruses.

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

K. Ardeshna, M. Lunning, P. Caimi, 2021, Clinical Lymphoma Myeloma and Leukemia.

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

J. Radford, K. Ardeshna, O. O’Connor, 2019, Clinical Cancer Research.

[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

A. Zelenetz, J. Friedberg, C. Flowers, 2017, Leukemia & lymphoma.

Non-Hodgkin's lymphomas, version 2.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2014 .

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

J. Byrd, R. Advani, J. Vose, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma

P. Moore, L. Ratner, M. Rudek, 2017, AIDS.

HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma

Sheldon R. Morris, E. Reid, S. Morris, 2012, Infectious Agents and Cancer.

Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Study

E. Cesarman, D. Dittmer, Jeannette Y Lee, 2012, Journal of acquired immune deficiency syndromes.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

R. Advani, J. Vose, L. Gordon, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

Huan-You Wang, E. Reid, Victoria A Chang, 2019, Blood advances.

Whole Transcriptome Sequencing Enables Discovery and Analysis of Viruses in Archived Primary Central Nervous System Lymphomas

Christopher M. DeBoever, K. Frazer, O. Harismendy, 2013, PloS one.

AMC-070: Lenalidomide is Safe and Effective in HIV-associated Kaposi Sarcoma.

T. Maurer, W. Wachsman, P. Moore, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bortezomib-induced Epstein–Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies

E. Reid, 2011, Current opinion in oncology.

What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?

C. Kane, K. Palazzi, F. Millard, 2014, International braz j urol : official journal of the Brazilian Society of Urology.

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2017 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

G. Salles, R. Bouabdallah, A. Chanan-Khan, 2019, Blood.

Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma

W. Wachsman, R. Gorelick, S. Lensing, 2019, Clinical Cancer Research.

Effects of Oxaliplatin, Carboplatin, and Cisplatin Across Treatment on High-Frequency Objective and Subjective Auditory Measures in Adults

J. Siegel, E. Reid, L. Dreisbach, 2017 .

A. LaCasce, M. Dwyer, Deborah A. Freedman-Cass, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.

E. Cesarman, L. Ratner, R. Baiocchi, 2015, Blood.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

C. Flowers, S. de Vos, L. Swinnen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)

E. Cesarman, J. Sparano, P. Moore, 2018, Clinical lymphoma, myeloma & leukemia.

Long-term survival in AIDS-related primary central nervous system lymphoma

P. Volberding, A. Omuro, J. Chavez, 2017, Neuro-oncology.

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

M. Rudek, Jeannette Y Lee, B. Dezube, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999–2008 and treated with curative intent in the AIDS Malignancy Consortium

P. Moore, L. Ratner, S. Lensing, 2012, Leukemia & lymphoma.

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

A. Tulpule, E. Cesarman, W. Tam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.

Richard D Moore, S. Cole, K. Richards, 2013, Journal of the National Cancer Institute.

Association of early HIV viremia with mortality after HIV-associated lymphoma

Richard D Moore, S. Cole, K. Richards, 2013, AIDS.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

R. Advani, J. Vose, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2016 .

Diffuse Large B-Cell Lymphoma Version 1.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

J. Radford, K. Ardeshna, O. O’Connor, 2020, Blood.

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

A. Zelenetz, J. Friedberg, C. Flowers, 2013 .

mTOR activity in AIDS-related diffuse large B-cell lymphoma

S. Vandenberg, Xiaoying Sun, Sonia Jain, 2017, PloS one.

Impact of Insurance Status on Outcomes in Individuals with AIDS-Defining Cancers.

E. Reid, Jun Yang Jiang, 2021, AIDS research and human retroviruses.

The American Society of Hematology (ASH) Medical Educators Institute: a Pilot Faculty Development Project for Hematology Educators

M. Kahn, C. Clayton, K. Zuckerman, 2019, Journal of Cancer Education.

Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial).

E. Cesarman, J. Sparano, P. Moore, 2020, Blood.

Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

E. Cesarman, J. Sparano, W. Wachsman, 2018, Blood advances.

Retinal vein occlusion during flare of multicentric Castleman’s disease

I. Kozák, E. Reid, 2013, Clinical ophthalmology.

An innovative system for 3D clinical photography in the resource-limited settings

Yu-Tseung Liu, S. Esener, D. Carson, 2014, Journal of Translational Medicine.

Autoimmune Hemolytic Anemia in HIV: A Case Series and Review of the Literature.

J. Caperna, E. Reid, David H Wu, 2006 .

ASTCT Clinical practice recommendations for transplant and cellular therapies in diffuse large B-cell lymphoma.

F. Awan, M. Perales, L. Lekakis, 2023, Transplantation and cellular therapy.

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

L. Swinnen, S. Wong, J. Ross, 2017 .

Frequency, Histologic, and Prognostic Significance of CD30 Expression in AIDS-associated Diffuse Large B-Cell Lymphoma

E. Cesarman, Camille E. Demarco, A. Chadburn, 2021, Blood.

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

C. Flowers, L. Swinnen, J. Cordero, 2015 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

T. Choueiri, G. Sonpavde, Douglas B. Johnson, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?

C. Kane, K. Palazzi, F. Millard, 2014, International braz j urol : official journal of the Brazilian Society of Urology.

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.

E. Cesarman, P. Moore, L. Ratner, 2023, The Lancet. Haematology.